Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer

FDA approves Anbogen’s ABT-301 trial for metastatic colorectal cancer

The US FDA has approved Anbogen Therapeutics’ IND application for the oral HDAC1/2/3 inhibitor ABT-301 in preparation for a Phase I/II trial.The post FDA approves Anbogen’s ABT-301 trial for metastatic colorectal cancer appeared first on Clinical Trials Arena.

Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer

TAIPEI, Aug. 4, 2025 /PRNewswire/ — Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ABT-301, enabling the initiation of a Phase 1/2 clinical trial in combination with tislelizumab and bevacizumab for patients with metastatic colorectal cancer (mCRC). This open-label, multi-center international study […] The post Anbogen Receives FDA Clearance to…

FDA Approves Application for ABT-301 in Metastatic Colorectal Cancer

The FDA approved an investigational new drug application for ABT-301, clearing the way for a new clinical trial in metastatic colorectal cancer to begin.

FDA Greenlights Novel Colorectal Cancer Triplet Therapy Trial

Anbogen Therapeutics gains FDA approval for ABT-301, initiating a pivotal trial for metastatic colorectal cancer, targeting unmet clinical needs.